November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Myeloma Paper of the Day, November 8th, suggested by Robert Orlowski
Nov 8, 2024, 13:40

Myeloma Paper of the Day, November 8th, suggested by Robert Orlowski

Robert Orlowski shared a post on X:

“Myeloma Paper of the Day: Results of a Phase 1b study analysis show 30-minute infusions of isatuximab are feasible and safe in patients with newly diagnosed multiple myeloma. Less time in the chair for patients saves money and improves satisfaction!”

30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis

Authors: Enrique M. Ocio, Aurore Perrot, Philippe Moreau, Maria-Victoria Mateos, Sara Bringhen, Joaquín Martínez-López, Lionel Karlin, Song-Yau Wang, Corina Oprea, Yi Li, Ercem Kodas, Jesus San-Miguel

Myeloma Paper of the Day, November 8th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.